Covea Finance’s BioMarin Pharmaceuticals BMRN Stock Holding History

Covea Finance’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.04M	Hold	140,500	–	–	0.25%	91
2026 Q1	$7.94M	Sell	140,500 -5,300	-4%	-$309K	0.28%	86
2025 Q4	$8.66M	Hold	145,800	–	–	0.29%	85
2025 Q3	$7.9M	Buy	145,800 +10,500	+8%	+$600K	0.28%	84
2025 Q2	$7.44M	Buy	135,300 +29,000	+27%	+$1.71M	0.28%	80
2025 Q1	$7.51M	Buy	106,300 +29,200	+38%	+$1.96M	0.34%	67
2024 Q4	$5.07M	Hold	77,100	–	–	0.23%	75
2024 Q3	$5.42M	Buy	77,100 +59,100	+328%	+$4.94M	0.24%	76
2024 Q2	$1.48M	Buy	+18,000	New	+$1.5M	0.07%	99

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Covea Finance's BMRN Position: Q2 2026 in Review

Covea Finance held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 140,500 shares worth $8.04M. The position accounts for 0.25% of the portfolio, ranked #91.

Covea Finance first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $8.66M in Q4 2025. 56 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Covea Finance held 140,500 shares of BioMarin Pharmaceuticals worth $8.04M as of Q2 2026.
Covea Finance left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.25% of Covea Finance's portfolio in Q2 2026, its #91 holding.
Covea Finance first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Covea Finance's BioMarin Pharmaceuticals position peaked at $8.66M in Q4 2025.
56 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Covea Finance's 13F filing for Q2 2026, filed 13 Jul 2026.